Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, and distributes various pharmaceutical products. It operates through two segments, Nichi-Iko Group and Sagent Group. The company primarily focuses on the production of generic drugs. It offers antidiabetic agents, antacids, antireflux agents, beta-blocker, hypnotic and sedative, angiotensin ? antagonist, angiotensin ? antagonist/diuretic combination, dyslipidaemic agent, and calcium antagonist products, as well as chemotherapeutic agents. The company also provides treatments for circulatory, digestive, respiratory, nervous system, allergies, and others. It supplies its products to medical institutions, including hospitals, clinics, dispensing pharmacies, etc. The company was formerly known as Nihon Iyakuhin Kogyo Co., Ltd. and changed its name to Nichi-Iko Pharmaceutical Co., Ltd. in 2005. Nichi-Iko Pharmaceutical Co., Ltd. was incorporated in 1947 and is headquartered in Toyama, Japan.

History

Nichi-Iko was established in Tokyo in 1965. We have grown from a small-scale drug producer to a leading international pharmaceutical company. We have conducted extensive research and development activities to identify and develop novel drugs, medical supplies, and diagnostic imaging equipment. Additionally, we have established subsidiaries and joint-ventures in over 40 countries worldwide. As a result, Nichi-Iko has become one of the largest pharmaceutical companies in Japan and one of the leading companies in the world.

Mission

Our mission is to be a leading international pharmaceutical company, providing innovative treatments and improving the quality of life for people around the world.

Vision

Our vision is to create a healthier world by delivering high-quality and effective treatments to patients, advancing research and development, and collaborating with global healthcare organizations to support access to healthcare.

Key Team

Mr. Takashi Kashiwagi (Sr. Exec. Officer & Head of Corp. Strategy & Planning Division)

Mr. Susumu Kanda (Managing Exec. Officer, GM of the Pres's Office & Director)

Mr. Hirotoshi Naruse (EVP, Managing Exec. Officer, GM of the Quality Control Division & Director)

Atsushi Matsumoto (Sr. Exec. Officer)

Tadashi Kojima (Sr. Exec. Officer)

Toru Furukawa (Sr. Exec. Officer)

Keiji Nagae (Sr. Exec. Officer)

Recognition and Awards

Nichi-Iko has been awarded numerous accolades for its excellence in research, business acumen and corporate social responsibility. We have been honored with the Prime Minister’s Prize for Excellence in Innovation, the Ministry of Health, Labour and Welfare's Prize for Promotion of Primary Care, and the Japan Quality Award.

References

https://in.investing.com/equities/nichi-iko-pharmaceutical

https://finance.yahoo.com/quote/4541.T/profile?p=4541.T

https://www.crunchbase.com/organization/nichi-iko-pharmaceutical

https://www.nichiiko.co.jp

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Leadership team

Mr. Yuiichi Tamura (Pres, CEO, Representative Director & Compliance Supervisor)

Mr. Shuji Ishida (EVP, GM of Admin. Division, Managing Exec. Officer & Director)

Hiroshi Shimazaki (Sr. Exec. Officer & Head of Quality Assurance & Pharmacovigilance Division)

Products/ Services

Biotechnology, Manufacturing, Pharmaceutical

Number of Employees

1,000 - 20,000

Headquarters

Toyama-shi, Toyama, Japan

Established

1965

Revenue

Above - 1B

Traded as

TYO:4541

URL

https://www.nichiiko.co.jp

Last updated: Tue Feb 25 2025

We value your privacy

Nichi-Iko Pharmaceutical

Table of content

Summary